drughunter.com
1 minute read
Oct. 25, 2024

Advancing Macrocycles in Drug Discovery

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other articles you may be interested in

Are Drugs Becoming More Lipophilic Over Time?

Drug lipophilicity is a core property that contributes to drug solubility, permeability, metabolic disposition, and other key properties. Increasing lipophilicity can often lead to increased affinity in relevant biological assays due to the hydrophobic nature of many protein binding pockets,  but this may also increase promiscuity to [...]

Small Molecules Evolve

Small molecule drugs make up most of the drugs we take conveniently as pills, including painkillers like ibuprofen (Advil), antibiotics like penicillin and amoxicillin, or cholesterol-lowering drugs like atorvastatin (Lipitor). The biotechnology revolution allowed scientists to create drugs through genetic engineering and related biological processes, creating a new category of drugs known as “biologics.”...

Patent Pulse: A Spotlight on Recent Highlights from Small Molecule Patents

As part of our Coffee Chat webinar series, our team (Lew Pennington, Matt Hesse, and Dennis Koester), explored Drug Hunter’s patent highlight feature and shared their favorite molecules and notable stories from recent patent filings. we present a PDF of the slide deck. Check out the recording of the talk on our Drug Hunter YouTube channel.

Olutasidenib: Potentially Longer Complete Remissions in AML with a Second-Generation IDH1 Inhibitor

Olutasidenib, discovered by Forma Therapeutics and marketed by Rigel, is an oral, brain-penetrant, selective mIDH1 inhibitor. It was granted Orphan Drug Designation and approved in December 2022 by the FDA for adults with relapsed/refractory acute myeloid leukemia. Approval was granted based on a Ph. I/II trial showing a 35% CR+CRh rate and a favorable 25.9-month median duration. This article describes the discovery and development of olutasidenib, how it is distinct from other mIDH inhibitors, and its potential in treating gliomas.

The Chemist's Playbook: Impactful Bioisosteres for Modern Drug Design

As part of our Flash Talk webinar series, we present a PDF of Nicholas Meanwell's slide deck entitled "The Chemist's Playbook: Impactful Bioisosteres for Modern Drug Design". Check out the recording of the talk on our Drug Hunter YouTube channel.